發(fā)布時間：2018-11-27 14:11

【摘要】：目的分析基質(zhì)金屬蛋白酶抑制劑伊洛馬司他聯(lián)合化療藥物卡培他濱對人喉癌Hep-2細(xì)胞增殖及凋亡的影響，初步探討伊洛馬司他在抗喉癌侵襲過程中的作用機制，為喉癌的聯(lián)合化療提供理論依據(jù)。 方法伊洛馬司他、卡培他濱兩藥單獨和聯(lián)合處理Hep-2細(xì)胞，未處理組為對照組，，采用MTT法分析Hep-2細(xì)胞的增殖活性，并采用金氏Q值判斷聯(lián)合用藥的性質(zhì)；流式細(xì)胞術(shù)檢測Hep-2細(xì)胞的凋亡率； RT-PCR檢測Hep-2細(xì)胞中MMP-9mRNA的表達(dá)水平。 結(jié)果①MTT示不同濃度伊洛馬司他與卡培他濱對Hep-2細(xì)胞的生長均有抑制作用，且抑制率呈濃度依賴性（P0.05）；聯(lián)合用藥后細(xì)胞抑制率明顯增高(P0.05)，且兩藥聯(lián)合濃度為（8+100）μg/ml作用時為協(xié)同作用，（40+400）μg/ml作用時為相加作用；②流式細(xì)胞術(shù)示伊洛馬司他單藥組及卡培他濱單藥組的凋亡率高于對照組（P0.05），聯(lián)合用藥組的凋亡率高于其它各組（P0.05）；③RT-PCR示伊洛馬司他單藥組與聯(lián)合用藥組的MMP-9mRNA的表達(dá)水平均低于對照組（P0.05），且聯(lián)合用藥組MMP-9mRNA的表達(dá)水平低于伊洛馬司他單藥組（P0.05），但卡培他濱單藥組與對照組間MMP-9mRNA的表達(dá)水平無統(tǒng)計學(xué)差異（P0.05）。 結(jié)論伊洛馬司他與卡培他濱聯(lián)合用藥可明顯增強單藥對喉癌Hep-2細(xì)胞的抑制效應(yīng)和誘導(dǎo)細(xì)胞凋亡作用，伊洛馬司他的作用機制可能是下調(diào)MMP-9的表達(dá)水平。
[Abstract]:Objective to investigate the effects of matrix metalloproteinase inhibitor iromatast combined with capecitabine on the proliferation and apoptosis of human laryngeal carcinoma Hep-2 cells, and to explore the mechanism of iromatrine in the process of anti-invasion of laryngeal carcinoma. To provide theoretical basis for combined chemotherapy of laryngeal carcinoma. Methods Hep-2 cells were treated with iromatrine and capecitabine alone or in combination, while the untreated group was used as control group. The proliferative activity of Hep-2 cells was analyzed by MTT assay, and the nature of combined treatment was determined by Kim's Q value. The apoptosis rate of Hep-2 cells was detected by flow cytometry and the expression of MMP-9mRNA in Hep-2 cells was detected by RT-PCR. Results 1MTT showed that the growth of Hep-2 cells was inhibited in a dose-dependent manner by different concentrations of iromatrine and capecitabine (P0.05). The cell inhibition rate was significantly increased after combined treatment (P0.05), and the synergistic effect was observed when the concentration of the two drugs was (8 100) 渭 g/ml, and the additive effect was (40 400) 渭 g/ml. 2 flow cytometry showed that the apoptotic rate of the single drug group and capecitabine group was higher than that of the control group (P0.05), and the apoptosis rate of the combination group was higher than that of the other groups (P0.05). The expression level of MMP-9mRNA in 3RT-PCR group and combination group was lower than that in control group (P0.05), and the level of MMP-9mRNA expression in combination group was lower than that in single drug group (P0.05). However, there was no significant difference in the expression of MMP-9mRNA between capecitabine group and control group (P0.05). Conclusion Iromatrine combined with capecitabine can significantly enhance the inhibitory effect and induce apoptosis of Hep-2 cells in laryngeal cancer. The mechanism of iromatrine may be to down-regulate the expression of MMP-9.
【學(xué)位授予單位】：南昌大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2013
【分類號】：R739.65

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 張秋穎;徐海艷;;聯(lián)合順鉑對卵巢癌細(xì)胞內(nèi)凋亡基因bax和bcl-2的影響[J];吉林醫(yī)學(xué);2012年08期

2 蘭菁;吳宜林;;GM6001對宮頸鱗癌HCE1多細(xì)胞球體浸潤人臍靜脈內(nèi)皮細(xì)胞的影響[J];中南大學(xué)學(xué)報(醫(yī)學(xué)版);2010年08期

3 王夢琦;陳志敏;;宮頸癌組織中MMP9表達(dá)及其對細(xì)胞增殖活性影響的臨床研究[J];中國現(xiàn)代藥物應(yīng)用;2010年12期

4 黃萬鐘;姚月華;鐘瑜;鮑潔;潘達(dá)超;;長春瑞濱聯(lián)合卡培他濱治療難治性鼻咽癌的臨床觀察[J];中國實用醫(yī)藥;2009年34期

5 趙建業(yè);朱鳴陽;楊術(shù)旺;趙紅艷;許威;;卡培他濱促進(jìn)胃癌細(xì)胞凋亡的實驗研究[J];武警醫(yī)學(xué)院學(xué)報;2008年12期

6 曹曉林;吳正虎;徐如君;林琳;張洋;朱瑾;李勇;;VEGF和TIMP-2蛋白在喉癌中的表達(dá)及其臨床意義[J];中國眼耳鼻喉科雜志;2008年03期

7 艾有琴;張劍;;血漿MMP-9在喉癌術(shù)后隨訪中的意義[J];實用臨床醫(yī)學(xué);2008年04期

8 劉鈺瑩;薛希均;王芳;;胸苷磷酸化酶、中期因子及CD105在喉癌組織中的表達(dá)及臨床意義[J];臨床耳鼻咽喉頭頸外科雜志;2008年03期

9 李為;劉衛(wèi)衛(wèi);白文忠;施惠晶;;MMP-7和TIMP-1在喉癌中的表達(dá)[J];中國耳鼻咽喉頭頸外科;2007年07期

10 王志新;徐飛;謝啟超;;肺癌組織MMP-7表達(dá)及其反義寡核苷酸對肺腺癌A_(549)細(xì)胞增殖的作用[J];四川醫(yī)學(xué);2006年11期

本文編號：2361066